Sean Duffy

Another milestone quarter for $OMDA. 📈 Revenue up 49% YoY to $68M 👥 831K members, up 53% YoY 📊 GAAP Net Loss narrowed to $3M 💫 First quarter of positive Adjusted EBITDA ($2M) Today we also announced significant steps forward in both AI capabilities and GLP-1 care options, including medication prescribing. These innovations reflect our commitment to delivering outcomes for members and cost-savings for customers on our mission to Bend the Curve. This year and next is truly the "year of the G's" - GLPs and GPTs - as we continue building the future of between-visit care. Read more about our Q3 performance, including a reconciliation of GAAP to Non-GAAP measures: tinyurl.com/ycx3kc2s

The GLP-1 era demands smart decisions on access, cost, and outcomes—now. At Omada, we're simplifying cardiometabolic care for a new era with over a decade of between-visit care innovation guiding us. Learn more: tinyurl.com/3sbejhcy

We’ve just reported Q425 and FY2025. It was a defining period for @OmadaHealth: We grew to 886K members (+55% YoY), delivered 53% revenue growth to $260M, and achieved our first quarter of GAAP profitability in Q4. A few highlights: 💡Positive adjusted EBITDA with significantly narrowed net loss in 2025 💡Q4 revenue of $76M, up 58% YOY 💡GAAP gross margin expanded to 66% for the year (71% in Q4), with non-GAAP gross margin reaching 68% for the year (73% in Q4) 💡More than 150,000 members supported on GLP-1s to date, alongside strong growth across our broader cardiometabolic suite. In many ways, I view 2025 as our launchpad – we’ve officially begun to see the benefit of many of our longstanding investments, all oriented to best serving our most important voices: our customers and our members in their pursuit of better health. Just so happens that I'm posting this on employee appreciation day. While the world sees the numbers, I see the thousands of hard working moments and the workforce behind them. This talented team fills me with pride, inspiration, and motivation every day. Grateful to every Omadan that got us here. What an exciting time for Omada. Now we get back to work bending the curve of chronic disease. Read more about our Q4 and end-of-year performance, including a reconciliation of GAAP to non-GAAP measures: bit.ly/40gcxnD $OMDA

When it comes to GLP‑1s, many employers feel stuck between “do nothing” and “all‑in coverage.” That’s not a great set of choices, especially when they want to find a way to say yes. I’m excited that @OmadaHealth is adding a new, flexible choice for our employer customers with GLP-1 Flex Care, a new option employers can offer directly to their workforce. With this launch, employers can: ✅ Add support in identifying GLP‑1 options even when pharmacy benefits are limited or closed ✅ Support GLP‑1 evaluation, lab ordering, prescribing, and virtual care for eligible members ✅ Keep medication purchases in established cash‑pay channels that arent charged to health plan spend It’s one more step toward giving organizations the flexibility they’ve been asking for as GLP‑1 demand and indications grow. In this dynamic market, we feel flexibility and adaptability matter enormously, and we love growing alongside our partners as their strategies evolve. Learn more: bit.ly/4rRacLQ

News! We’re adding Omada for Cholesterol to @OmadaHealth’s integrated platform. The launch is in partnership with a big, longstanding customer – our preferred way to innovation. And Omada’s flexible infrastructure lets us stand up new capabilities quickly. This brings focused cholesterol care into the same between‑visit model that already supports obesity, diabetes, hypertension, and GLP‑1 support. Grateful to our teams and customers for the collaboration that got us here. buff.ly/qITp9P8

The recent White House announcement on GLP-1 pricing marks a pivotal shift in obesity care - and it’s exciting to see these medications become more accessible I believe that true success will depend on ensuring the right support for lasting outcomes, and I'm proud to share @OmadaHealth's new prescribing offering for anti-obesity medications, including GLP-1s. It combines sophisticated clinical protocols, motivational readiness, and behavioral data to support prescribing decisions and medication management for members’ weight health journey. This new capability is an important tool to achieve our mission: Bend the Curve. Learn more: tinyurl.com/mr2djtf6

Today marks $OMDA's first earnings as a public company. 📈 Revenue up 49% YoY to $61M 👥 Members up 52% YoY to 752K 💪 Strong margin improvements and progress toward profitability What started as a sketch on a whiteboard has grown into a Between-Visit Care model now scaling to 752K active members (up 52% YoY). With expanding GLP-1care track capabilities, new artificial intelligence capabilities, and growing partnerships, @OmadaHealth’s Q2 results show strong momentum in a large addressable market. Thank you to our members, customers, and Omadans. We're just getting started on our mission to bend the curve of chronic disease. tinyurl.com/macrewt7

@StuartBlitz 😂 interplanetary expansion

Crazy you can found a health tech company, lead it to an IPO, and land this job right after

@cwhogg Thanks, Chris! Please send feedback! It’s day 1 for the app.

@seanduffy Just downloaded. Sounds so fun.

Wow, my landscape architect wife Janice is incredible. She just launched Vera, an iOS app that after reflecting, may be the most innovative contribution in her entire field... to date. It allows homeowners to snap a satellite image of their yard and drag and drop 100+ amenities - at accurate scale - to help create a yard planning vision. Want a fire pit? It fits! How about a playground for the kiddos? Outdoor dining area? Tuck it in! Please try it and give her feedback. It is day one, and knowing her and her commitment to excellence, it is just the beginning! apps.apple.com/us/app/landsca…

Omada was one of the first deals I did as an investor. They grinded it out for a decade. Well deserved. a16z.com/software-gets-…

Overnight success, ten years in the making. Congrats to @seanduffy and the Omada team on their IPO.

What can the global market learn from the U.S. about GLP-1s? Omada CEO @SeanDuffy wrote about this in collaboration with @WEF to coincide with his participation at the annual meeting in Davos, Switzerland. Read it here: tinyurl.com/8m8cw8na

@chrissyfarr We are @omadahealth. Many great roles open and more coming. omadahealth.com/about-us/caree…

Who in digital health is hiring going into 2025? I’ve got a variety of amazing folks in my network looking.

@B_Madden4 Feel free to heckle me on Tues. ;)

JPM co's I'm interested in getting updates on:

@StuartBlitz Not Omada. Blessed with reasonable metabolic health in immediate circles. Panicked while studying epidemiological trajectory of US wrt chronic disease & decided I needed to contribute.

Pretty convinced every successful health tech company was started for *only* one of two reasons: 1) Personal health experience 2) In response to a trauma a founder had at previous jobs

To all future air travelers: No, I didn't personally delay your flight. That's the OTHER Sean Duffy. 😉 axios.com/2024/11/18/tru…

@dvansickle !!!!

Excited to get the Propeller team back together to re-imagine the iron lung #timetobuild

CBO's lens is pretty narrow - strictly economic. It looks at improved health but only to the extent that improved health reduces utilization and potentially avoids costs. So there is no Quality-adjusted life year measurement or anything similar. Myopic but useful relative to simple questions around budgeting for new medical innovations.

@seanduffy Curious, does CBO put any value on improved health, or just calculate costs avoided? E.g., if I avoid a heart attack, do they just count the healthcare costs I avoided by not going to the hospital and getting a procedure, or is there value ascribed to my increased health?

Curious about the economic impact if Medicare were to cover GLP-1s for Obesity? Yesterday, the Congressional Budget Office (CBO) — a nonpartisan agency that provides budgetary analysis for Congress — issued a report on the potential costs and benefits of Medicare covering anti-obesity medications (AOMs): cbo.gov/publication/60… A few of the key findings: 1.) Covering AOMs could increase federal spending by $35.5 billion between 2026 and 2034. 2.) Health savings from improved outcomes would rise, but fall short of the costs. Small savings of $50M in 2026 (against costs of $1.6B), scaling up to $1B savings (against costs of $7.1B) by 2034. 3.) 12.5M Medicare beneficiaries could become eligible for AOMs by 2026, with 2% projected to use them initially. 4.) Average cost per user in the analysis starts at $5,600 in 2026, dropping to $4,300 by 2034. Savings per user are significantly smaller: just $50 in 2026, growing to $650 by 2034. 5.) The report highlights the uncertainty around future prices, uptake, and health outcomes, yet long-term spending is still expected to increase. So I suppose we’re at status quo? Net if Medicare were to cover AOMs, it’d involve a complex trade-offs between costs and health. And net is that we're still early. There are a bolus of assumptions in this analysis that I'm sure will be refined on the road ahead. We have a lot to learn about how we best utilize what are exceptional tools in the toolkit against Obesity, but are not a silver bullet. #Medicare #Obesity #CBO #AOM #HealthCarePolicy